Q1 FY27 delivered 22% YoY revenue growth, 60% PAT growth, and margin expansion, driven by a shift to complex generics now comprising 50% of finished dosages. Strong cash flow, improved capital efficiency, and robust R&D pipeline position the business for sustainable growth.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.